Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vor Biopharma Inc. - Common Stock (NQ:VOR)

1.930 -0.070 (-3.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vor Biopharma Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel
Experienced legal leader brings deep expertise in governance, strategic transactions, and risk management to support Vor Bio’s growth 
From Vor Biopharma
Via GlobeNewswire
FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari
FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing. 
Via Benzinga
Vor Bio's Investigational Drug Scores Phase 3 Win In Autoimmune Kidney Disease Trial
Vor Bio partner RemeGen reports Phase 3 success for telitacicept in IgA nephropathy, showing a 55% drop in proteinuria and plans for a China BLA filing. 
Via Benzinga
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy
From Vor Biopharma
Via GlobeNewswire
Vor Bio Stock Jumped 19% Today And Retail Investors Are Eyeing A Breakout Rally: Here’s What’s Happening
Via Stocktwits
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate
Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's disease. 
Via Benzinga
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor
From Vor Biopharma
Via GlobeNewswire
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
Experienced commercial leader to shape launch strategy and global market readiness for telitacicept and future pipeline opportunities 
From Vor Biopharma
Via GlobeNewswire
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors
From Vor Biopharma
Via GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
From Vor Biopharma
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer
From Vor Biopharma
Via GlobeNewswire
Why ENDRA Life Sciences Shares Are Trading Higher By Over 61%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Top stock movements in today's session.
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Here are the top movers in Monday's session.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Top stock movements in today's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
These stocks have an unusual volume in today's session
On Tuesday, there are stocks with unusual volume. Let's take a look. 
Via Chartmill
Let's take a look at the stocks that are in motion in today's session.
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market
Vor Biopharma gains rights to autoimmune drug telitacicept, raises capital and names a new CEO in a major strategic reset. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Which stocks have an unusual volume on Monday?
Unusual volume stocks are being observed in Monday's session. 
Via Chartmill
This Oracle Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
 
Via Benzinga
Which stocks are moving on Monday?
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
Which stocks are experiencing notable movement on Friday?
Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.